AXL is an oncotarget in human colorectal cancer

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23281-23296

  Martinelli, Erika ^a   Martini, Giulia ^a   Cardone, Claudia ^a   Troiani, Teresa ^a   Liguori, Giuseppina ^b   Vitagliano, Donata ^a   Napolitano, Stefania ^a   Morgillo, Floriana ^a   Rinaldi, Barbara ^a   Melillo, Rosa Marina ^c   Liotti, Federica ^c   Nappi, Anna ^b   Bianco, Roberto ^d   Berrino, Liberato ^a   Ciuffreda, Loreta Pia ^a   Ciardiello, Davide ^a   Iaffaioli, Vincenzo ^b   Botti, Gerardo ^b   Ferraiolo, Fiorella ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AXL; Colorectal cancer; FISH; Foretinib; GAS6

Indexed keywords

AXL PROTEIN; GROWTH ARREST SPECIFIC PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN S6; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANILIDE; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; FORETINIB; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; PROTEIN TYROSINE KINASE; QUINOLINE DERIVATIVE; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXL GENE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GAS6 GENE; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RNA INTERFERENCE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL MOTION; CHEMISTRY; COLORECTAL NEOPLASMS; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; HCT 116 CELL LINE; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; FEMALE; GENE SILENCING; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; QUINOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE;

EID: 84943411277     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3962     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J Clin. 2011;61:212-36.
2. Jemal A, Bray F, Cenet MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol. 2015 Jan 20.
4. Van Cutsem E, Cervantes A, Nordlinger B & Arnold D, on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 25 (suppl 3).
5. Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F. Emerging VEGF receptor inhibitors for colorectal cancer. Expert Opinion On Emerging Drugs. 2012;18:1472-8214.
6. Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on biological therapy. 2013;13:1471-2598.
7. Linger, R. Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases:biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 2008;100:35-83.
8. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 2008;8:327-336.
9. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Merkinases in cancer. Mol Cancer Ther. 2011;10:1763-73.
10. Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM, Strausberg RL, Simpson AJ, Jardim DL, Reis LF, et al. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. Oncotarget. 2014;5:9199-213.
11. Fleuren ED, Hillebrandt-Roeffen MH, Flucke UE, Te Loo DM, Boerman OC, Van der Graaf WT, VersleijenJonkers YM. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. Oncotarget. 2014;5:12753-68.
12. Axelrod H, Pienta KJ. Axl as a mediator of cellular growth and survival. Oncotarget. 2014;5:8818-52.
13. Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;5:9546-63.
14. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010.
15. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther. 2009;8:618-26.
16. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 2002;22:1071-1080.
17. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol. 2005;204:36-44.
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, et al. Multideterminants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. 2009;PLoS One 4:e7287.
19. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer:the PRIME study. J Clin Oncol 2010;28:4697-4705.
20. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EgFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
21. Bardelli A, Siena S. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. J Clin Oncol 2010;8:1254-1261.
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer:a retrospective consortium analysis. Lancet 2010;11:753-762.
23. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, et al. Increased TGFa as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clinical Cancer Research. 2013;19:6751-6765.
24. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer research. 2009;69:8009-8016.
25. Dienstmann R, Salazar R, Tabernero J. The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning. 2014, ASCO Educational Book.
26. Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J. Higher expression of receptors tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Annals of surgical oncology. 2013;20:S467-476.
27. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011;2:874-85.
28. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 1;44(8):852-60.
29. Bae SY, Hong JY, Lee HJ, Park HJ, Lee SK. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget. 2015 Feb 26. [Epub ahead of print].
30. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL Mediates Resistance to Cetuximab Therapy. Cancer Res 2014;18:5152-5164.
31. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to antiepidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res. 2008 Aug 15;14(16):5069-80.
32. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012;139:3471-3486.
33. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science translational medicine. 2011;3:75-86.
34. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cáncer. Oncogene. 2011;30:1436-1448.
35. Asiedu MK, Beauchmanp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelialto-mesenchymal transition and regulates function of breast cancer stem cells. Oncogene. 2014;33:1316-1324.
36. Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;20:9546-9563.
37. Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, Lee JC. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014 74:253-66.
38. Sørensen V, Zhen Y, Zakrzewska M, Haugsten EM, Wälchli S, Nilsen T, Olsnes S, Wiedlocha A. Phosphorylation of Fibroblast Growth Factor (FGF) Receptor 1 at Ser777 by p38 Mitogen-Activated Protein Kinase Regulates Translocation of Exogenous FGF1 to the Cytosol and Nucleus. Molecular and cellular biology. 2008:4129-4141.
39. Craven RJ. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J. cancer. 1995;60:791-797.
40. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T. Axl is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clinical Cancer Res. 2014;20:164-175.